J. Wildiers

1.9k total citations
34 papers, 1.5k citations indexed

About

J. Wildiers is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Wildiers has authored 34 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Wildiers's work include Cancer Treatment and Pharmacology (10 papers), Breast Cancer Treatment Studies (10 papers) and Estrogen and related hormone effects (5 papers). J. Wildiers is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Breast Cancer Treatment Studies (10 papers) and Estrogen and related hormone effects (5 papers). J. Wildiers collaborates with scholars based in Belgium, Netherlands and Italy. J. Wildiers's co-authors include Richard Sylvester, Robert Paridaens, Erik De Clercq, J.G.M. Klijn, F. Cognetti, Nicole Rotmensz, Jan H. Schornagel, M. Clavel, E Engelsman and P.F. Bruning and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The American Journal of Medicine.

In The Last Decade

J. Wildiers

34 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Wildiers Belgium	18	965	492	333	240	182	34	1.5k
Narin Voravud Thailand	23	700 0.7×	408 0.8×	247 0.7×	253 1.1×	833 4.6×	65	2.0k
Charalambos Kouroussis Greece	18	1.0k 1.1×	325 0.7×	752 2.3×	88 0.4×	264 1.5×	49	1.5k
Vito Rodolico Italy	24	457 0.5×	188 0.4×	215 0.6×	199 0.8×	487 2.7×	79	1.6k
Maarten P. Tabor Netherlands	9	833 0.9×	405 0.8×	342 1.0×	826 3.4×	653 3.6×	11	2.1k
Jerri Linn Phillips United States	19	1.2k 1.3×	276 0.6×	1.1k 3.2×	161 0.7×	403 2.2×	31	2.8k
Asawari Patil India	16	380 0.4×	151 0.3×	224 0.7×	212 0.9×	196 1.1×	88	927
Jayaprakash Madhavan India	19	863 0.9×	197 0.4×	1.1k 3.2×	66 0.3×	456 2.5×	40	1.9k
Hideo Niibe Japan	24	440 0.5×	139 0.3×	787 2.4×	165 0.7×	304 1.7×	143	1.7k
Avi B. Markowitz United States	16	561 0.6×	89 0.2×	383 1.2×	97 0.4×	245 1.3×	35	1.1k
Sana Intidhar Labidi‐Galy Switzerland	23	1.6k 1.6×	295 0.6×	358 1.1×	49 0.2×	410 2.3×	55	2.4k

Countries citing papers authored by J. Wildiers

Since Specialization

Citations

This map shows the geographic impact of J. Wildiers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Wildiers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Wildiers more than expected).

Fields of papers citing papers by J. Wildiers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Wildiers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Wildiers. The network helps show where J. Wildiers may publish in the future.

Co-authorship network of co-authors of J. Wildiers

This figure shows the co-authorship network connecting the top 25 collaborators of J. Wildiers. A scholar is included among the top collaborators of J. Wildiers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Wildiers. J. Wildiers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paridaens, Robert, F. Van Aelst, Vassilis Georgoulias, et al.. (2003). A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. Annals of Oncology. 14(3). 433–440. 18 indexed citations

Fentiman, Ian S., Marie-Rose Christiaens, Robert Paridaens, et al.. (2003). Treatment of operable breast cancer in the elderly. European Journal of Cancer. 39(3). 309–316. 82 indexed citations

Nooij, M., J.C.J.M. de Haes, L.V.A.M. Beex, et al.. (2003). Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. European Journal of Cancer. 39(5). 614–621. 36 indexed citations

Paridaens, Robert, J. Wildiers, Herlinde Dumez, et al.. (2002). Impact of dose-intensity of adjuvant CMF on disease-free (DFS) and overall survival (OS) in breast cancer (BC): a retrospective analysis. Annals of Oncology. 13. 45–45. 8 indexed citations

Paridaens, Robert, Laura Biganzoli, P.F. Bruning, et al.. (2000). Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over. Journal of Clinical Oncology. 18(4). 724–724. 288 indexed citations

Vinholes, J., RE Coleman, Denis Lacombe, et al.. (1999). Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. British Journal of Cancer. 80(1-2). 221–228. 50 indexed citations

Mauriac, L., Corinne Veyret, J. Wildiers, et al.. (1998). Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881. Ghent University Academic Bibliography (Ghent University). 8 indexed citations

Bontenbal, M., Maria Andersson, J. Wildiers, et al.. (1998). Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. British Journal of Cancer. 77(12). 2257–2263. 41 indexed citations

Paridaens, Robert, José Thomas, J. Wildiers, et al.. (1998). Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anti-Cancer Drugs. 9(8). 675–683. 36 indexed citations

10.

Schornagel, Jan H., Jaap Verweij, F. Cognetti, et al.. (1995). Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.. Journal of Clinical Oncology. 13(7). 1649–1655. 64 indexed citations

11.

Paridaens, Robert, Jan Lemmens, Erik Van Limbergen, et al.. (1995). 48 Influence of concomitant radiotherapy on dose intensity of adjuvant CMF in patients with node-positive breast cancer. European Journal of Cancer. 31. S12–S12. 1 indexed citations

12.

Clavel, M., Jan B. Vermorken, F. Cognetti, et al.. (1994). Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology. 5(6). 521–526. 210 indexed citations

13.

Schornagel, Jan H., Jaap Verweij, F. Cognetti, et al.. (1992). A phase II trial of 10-Ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. Annals of Oncology. 3(3). 223–226. 17 indexed citations

14.

Engelsman, E, R.D. Rubens, J. Wildiers, et al.. (1991). “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. European Journal of Cancer and Clinical Oncology. 27(8). 966–970. 122 indexed citations

15.

Bruning, P.F., Johannes M.G. Bonfrèr, J. Wildiers, et al.. (1990). Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-ARM randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861). The Journal of Steroid Biochemistry and Molecular Biology. 37(6). 1013–1019. 1 indexed citations

16.

Rubens, R.D., Harry Bartelink, E Engelsman, et al.. (1989). Locally advanced breast cancer: The contribution of cytotoxic and endocrine treatment to radiotherapy. European Journal of Cancer and Clinical Oncology. 25(4). 667–678. 73 indexed citations

17.

Wildiers, J., K. Vantongelen, J.A. van Dongen, Nicole Rotmensz, & Richard Sylvester. (1988). Activities of the EORTC Breast Cancer Co-operative Group: an overview. European Journal of Cancer and Clinical Oncology. 24(1). 3–8. 5 indexed citations

18.

Bijvoet, O. L. M., Jean‐Jacques Body, Jan Willem F. Elte, et al.. (1987). Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. The American Journal of Medicine. 82(6). 1133–1142. 77 indexed citations

19.

Clercq, Erik De, H. Degreef, J. Wildiers, et al.. (1980). Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster.. BMJ. 281(6249). 1178.1–1178. 108 indexed citations

20.

Eyckmans, L, et al.. (1968). Pigeon Breeder's Lung. Diseases of the Chest. 53(3). 358–364. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact